Anteris Technologies Ltd (ASX:AVR)

ALERT: Price-sensitive ASX Announcement for AVR

Current share price for AVR : $15.300 6.71 (78.11%)⁺

Announcement

Quarterly Results Announcement and SEC Form 10-Q

Release

13 May 2026 8:22AM

Price at Release

$8.590

Full Release

Summary

Anteris Technologies Ltd released its quarterly results for the period ending March 31, 2026, reporting a comprehensive loss of $22.8 million. The financial statements, prepared in line with U.S. GAAP, indicate significant activities, including $2.3 million in related-party payments and the issuance of over 55 million shares, boosting the capital raised to $308.3 million. These proceedings reflect Anteris' ongoing commitment to advancing its medical device offerings for heart disease. The company, operational in both Australia and the USA, experienced a net cash usage of $28.7 million in operating activities, underscoring its focus on strategic growth and development in the structural heart disease arena.

Key Points

Anteris Technologies Global Corp. reported a comprehensive loss of $22.8 million for the first quarter of 2026.
The company's consolidated financial statements are prepared in accordance with U.S. GAAP.
During the quarter, Anteris made aggregate payments of $2.3 million to related parties and their associates.
The company issued 55,652,173 shares of common stock, resulting in an increase in additional paid-in capital.
Anteris Technologies is focused on designing and commercializing medical devices for structural heart disease.
The company maintains a significant presence in both Australia and the USA.
Net cash used in operating activities was $28.7 million for the quarter.
The company reported $308.3 million in proceeds from the issuance of shares.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.